Contego Medical Announces One-Year Outcomes From The Performance II Carotid Stent Trial

RALEIGH, N.C., Nov. 1, 2023 /PRNewswire/ -- Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced the presentation of late-breaking clinical results from the PERFORMANCE II carotid stent trial at the annual VIVA (Vascular InterVentional Advances) multidisciplinary vascular education conference. PERFORMANCE II is a prospective, multicenter study evaluating the safety and effectiveness of the Neuroguard IEP® System in 305 patients at 40 clinical sites.

By |2023-11-01T13:01:05-07:00November 1st, 2023|News|Comments Off on Contego Medical Announces One-Year Outcomes From The Performance II Carotid Stent Trial

Contego Medical Announces Presentation of Results From Performance II Carotid Stent Trial at Viva23

RALEIGH, N.C., Oct. 30, 2023/-- Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced the completion of 1-year follow-up visits for patients in the PERFORMANCE II Carotid Stent Trial and the upcoming presentation of 30-day and 1-year results at the VIVA (Vascular InterVentional Advances) meeting.

By |2023-11-01T13:00:34-07:00October 30th, 2023|News|Comments Off on Contego Medical Announces Presentation of Results From Performance II Carotid Stent Trial at Viva23

Contego Medical Announces Start of Enrollment in Performance III Direct Transcarotid Access Stenting Trial

RALEIGH, NC, October 6, 2023 /PRNewswire/ -- Contego Medical, Inc. a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced enrollment of the first patient in the PERFORMANCE III Trial.  PERFORMANCE III is a prospective, multicenter trial aimed at further evaluating the safety and effectiveness of the Neuroguard IEP® Direct System, a carotid stent system designed for direct transcarotid access. 

By |2023-10-31T06:44:57-07:00October 6th, 2023|News|Comments Off on Contego Medical Announces Start of Enrollment in Performance III Direct Transcarotid Access Stenting Trial

Contego Medical Completes Enrollment of the PERFORMANCE II Carotid Stent Trial

RALEIGH, NC, November 14, 2022 /PRNewswire/ -- Contego Medical, Inc. announced that enrollment of the PERFORMANCE II clinical trial has been completed. PERFORMANCE II is designed to evaluate the safety and effectiveness of the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is designed to treat clinically significant carotid artery stenosis while improving procedural safety through the integration of the stent, balloon and an embolic filter all in a single device.

By |2023-10-31T06:45:31-07:00November 14th, 2022|News|Comments Off on Contego Medical Completes Enrollment of the PERFORMANCE II Carotid Stent Trial

Contego Medical Announces Hiring of Steve MacKinnon, Chief Commercialization Officer

RALEIGH, N.C., Feb. 10, 2022 /PRNewswire/ -- Contego Medical has announced that Steve MacKinnon has joined the organization as their Chief Commercialization Officer. Mr. MacKinnon is an accomplished senior medical device executive with significant commercialization experience, a track record of success, and a history of driving growth by building and managing highly motivated sales teams. In his role, Mr. MacKinnon will be responsible for launching a portfolio of innovative and state-of-the-art medical devices that will redefine the treatment of cardiovascular disease.

By |2023-10-31T06:46:35-07:00March 14th, 2022|News|Comments Off on Contego Medical Announces Hiring of Steve MacKinnon, Chief Commercialization Officer

Contego Medical, Inc. announced receipt of CE Mark approval for the Neuroguard IEP®

RALEIGH, N.C., April 16, 2021/PRNewswire/ — Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).

By |2021-04-26T05:26:27-07:00April 26th, 2021|News|Comments Off on Contego Medical, Inc. announced receipt of CE Mark approval for the Neuroguard IEP®

Contego Medical Announces the Start of Enrollment in the PERFORMANCE II Carotid Stenting Clinical Trial

RALEIGH, N.C., June 15, 2020 /PRNewswire/ -- Contego Medical, Inc. today announced enrollment of the first patient in the PERFORMANCE II Trial evaluating the safety and effectiveness of the Neuroguard IEP® 3 in 1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is designed to treat clinically significant carotid artery stenosis while improving procedural safety through the integration of stent, balloon and filter technology all in a single device. The first patient was treated at University of North Carolina Rex Hospital in Raleigh, North Carolina by James Zidar, M.D., FACC, FSCAI.

By |2022-12-15T23:36:00-08:00March 4th, 2021|News|Comments Off on Contego Medical Announces the Start of Enrollment in the PERFORMANCE II Carotid Stenting Clinical Trial

Contego Medical Receives 510(k) Clearance for the Vanguard IEP Peripheral Angioplasty System with Integrated Embolic Protection

Raleigh, NC (December 07, 2018) -- Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Vanguard IEP® Peripheral Balloon Angioplasty System with Integrated Embolic Protection. Contego Medical is a medical device company developing and commercializing a suite of next-generation devices that address unmet needs in neurovascular, coronary and peripheral vascular disease.

By |2022-12-15T23:36:00-08:00December 10th, 2018|News|Comments Off on Contego Medical Receives 510(k) Clearance for the Vanguard IEP Peripheral Angioplasty System with Integrated Embolic Protection

Contego Medical Receives 510(k) Clearance for the Paladin Carotid PTA Balloon System with Integrated Embolic Protection

Raleigh, NC (September 18, 2018) — Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first filter-based Integrated Embolic Protection (IEP) device, the Paladin® Carotid PTA Balloon System. Contego Medical is developing and commercializing a suite of next-generation devices that address unmet needs in neurovascular, coronary and peripheral [...]

By |2018-10-16T10:54:48-07:00October 16th, 2018|News|Comments Off on Contego Medical Receives 510(k) Clearance for the Paladin Carotid PTA Balloon System with Integrated Embolic Protection

Contego Medical Announces the Start of Enrollment in the PERFORMANCE I Trial

Raleigh, NC, March 7, 2018 -- Contego Medical, LLC has announced the beginning of enrollment in the PERFORMANCE I Trial, a clinical trial designed to evaluate the safety and feasibility of the Neuroguard IEPâ 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is designed to treat clinically significant carotid artery stenosis, further expanding Contego Medical’s portfolio of neurovascular solutions.

By |2023-01-04T10:10:08-08:00March 7th, 2018|News|Comments Off on Contego Medical Announces the Start of Enrollment in the PERFORMANCE I Trial
Go to Top